Xenothera Announces Publication in European Journal of Clinical Investigation on Immunological Mechanisms Underlining Use of LIS1

Kidney graft recipients receiving anti-lymphocyte globulins of animal origin undergo unwanted immune responses against Neu5GC carbohydrate antigens related to safety concerns, endothelial inflammation and possibly rejection. Xenothera’s LIS1 is a next-generation engineered Anti-Lymphocyte Globulins which does not elicit responses against Neu5GC carbohydrate antigens. Nantes, February 28, 2019 – Xenothera announced publication in European Journal of Clinical Investigation of data detailing the expected benefit of LIS1 for kidney graft recipients. To keep the immune system in check, physicians use anti-lymphocyte globulins to deplete T lymphocytes and prevent rejection. Anti-lymphocyte globulins are polyclonal IgG preparation from animal origin, potentially immunogenic in humans because of presence of Neu5GC carbohydrate antigens. Xenothera collaborated with Universities of Tel Aviv, Prague, California-Davis, Nantes and with the Veterinary School of Nantes to demonstrate that anti-lymphocyte globulins indeed elicit strong anti-Neu5GC antibodies in kidney graft recipient and that this response comprises new reactivities that might be associated with formation of immune complexes, damage endothelial cells, elicit inflammation and are associated with shorter kidney graft lifespan. Using its next-generation polyclonal antibody platform, Xenothera is developing LIS1, a novel engineered anti-lymphocyte globulins which does not elicit anti-Neu5GC antibodies in humans. Odile Duvaux, CEO of Xenothera said “We warmly congratulate the Xenothera’s team and collaborators involved in this achievement. LIS1 is about to enter clinical development, for the benefit of patients who suffer from suboptimal outcomes of their kidney graft”. Quantitative and qualitative changes in anti-Neu5Gc antibody response following rabbit anti-thymocyte IgG induction in kidney allograft recipients. Rousse J 1 , Salama A 1 , Leviatan Ben-Arye S 2 , Hruba P 3 , Slatinska J 4 , Evanno G 1 , Duvaux O 1 , Blanchard D 1 , Yu H 5 , Chen X 5 , Bach JM 6 , Padler-Karavani V 2 , Viklicky O 3,4 , Soulillou JP 7,8 . Eur J Clin Invest. 2019 Jan 8:e13069. doi: 10.1111/eci.13069. https://www-ncbi-nlm-nih-gov.gate2.inist.fr/pubmed/30620396 1 Xenothera, Nantes, France. 2 Department of Cell Research and Immunology, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel. 3 Transplant Laboratory, Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. 4 Department of Nephrology, Transplant Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. 5 Department of Chemistry, University of California-Davis, Davis, California. 6 Immuno-Endocrinology Unit, EA4644 University/ONIRIS USC1383 INRA, Pathophysiology Department, ONIRIS-Nantes-Atlantic College of Veterinary Medicine and Food Sciences, Nantes, France. 7 Centre de Recherche en Transplantation et Immunologie, UMR 1064, INSERM, Université de Nantes, Nantes, France. 8 Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France.

The release as fetched from its publisher. xenothera.com ↗